Showing results (641-650 of 1,008) with videos related to
Sort By:
Pageof 101
Cardiovascular Therapeutics|January 30, 2013
Deficiency of a new protein associated with cardiac syndrome X; called adropinAhmet Celik, Mehmet Balin, Mehmet Ali Kobat, et al.Cardiovascular Therapeutics|January 3, 2013
Anticoagulation in patients with dilated cardiomyopathy, low ejection fraction, and sinus rhythm: back to the drawing boardAlexandru Nicolae Mischie, Valentin Chioncel, Ionel Droc, et al.Cardiovascular Therapeutics|January 15, 2013
Prasugrel reduces agonists' inducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrelThomas Gremmel, Roza Badr Eslam, Renate Koppensteiner, et al.Cardiovascular Therapeutics|January 15, 2013
Age and sex effects on the single- and multiple-dose safety and pharmacokinetics of the new renin inhibitor ACT-178882Jasper Dingemanse, Laurent NicolasCardiovascular Therapeutics|October 8, 2014
Different effects of fenofibrate on metabolic and cardiovascular risk factors in mixed dyslipidemic women with normal thyroid function and subclinical hypothyroidismRobert Krysiak, Wojciech Gilowski, Witold Szkrobka, et al.Cardiovascular Therapeutics|June 19, 2013
Epidemiology of CYP3A4-mediated clopidogrel drug-drug interactions and their clinical consequencesTuire Tirkkonen, Pekka Heikkilä, Tero Vahlberg, et al.Cardiovascular Therapeutics|October 22, 2013
Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilatJonathan R Dalzell, Alison Seed, Colin Berry, et al.Cardiovascular Therapeutics|October 11, 2013
Influence of feeding and intracoronary dose on insulin-mediated relative akt phosphorylation in the porcine myocardiumGrete Slettom, Anne Kristine Jonassen, Lars Breivik, et al.Cardiovascular Therapeutics|October 12, 2013
Geometry of the randomized evidence for treatments of pulmonary hypertensionAdriano R Tonelli, Joe Zein, John P A IoannidisCardiovascular Therapeutics|July 12, 2013
Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertensionShelley Shapiro, Glenna Traiger, Wendy Hill, et al.Pageof 101